The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive ...

Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...

(Reuters) - The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing ...

Tandem Diabetes Care ( TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system ...

“The market’s robust growth trajectory reflects the increasing demand for more effective and user-friendly insulin delivery ...